Dipartimento di Neuroscienze, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto di Ricerche Farmacologiche Mario Negri, via La Masa 19, 20156 Milano, Italy; These authors contributed equally to this work.
Dipartimento di Chimica, Materiali e Ingegneria Chimica 'Giulio Natta', Politecnico di Milano, via Mancinelli 7, 20131 Milano, Italy.
Trends Mol Med. 2017 Sep;23(9):831-849. doi: 10.1016/j.molmed.2017.07.005. Epub 2017 Aug 12.
Spinal cord injury (SCI) is a complex pathology that evolves after primary acute mechanical injury, causing further damage to the spinal cord tissue that exacerbates clinical outcomes. Based on encouraging results from preclinical experiments, some cell treatments being translated into clinical practice demonstrate promising and effective improvement in sensory/motor function. Combinatorial treatments of cell and drug/biological factors have been demonstrated to be more effective than cell treatments alone. Recent advances have led to the development of biomaterials aiming to promote in situ cell delivery for SCI, together with combinatorial strategies using drugs/biomolecules to achieve a maximized multitarget approach. This review provides an overview of single and combinatorial regenerative cell treatments as well as potential delivery options to treat SCI.
脊髓损伤(SCI)是一种复杂的病理学,在原发性急性机械损伤后发展,导致脊髓组织进一步损伤,从而恶化临床结局。基于临床前实验的鼓舞人心的结果,一些正在转化为临床实践的细胞治疗方法显示出在感觉/运动功能方面有很有前景和有效的改善。细胞与药物/生物因子的组合治疗已被证明比单独的细胞治疗更有效。最近的进展导致了旨在促进脊髓损伤部位细胞递送来的生物材料的发展,以及使用药物/生物分子的组合策略来实现最大化的多靶点方法。本综述概述了单一和组合的再生细胞治疗以及治疗 SCI 的潜在递药选择。